Προσδιορισμός του δείκτη κόστους αποτελεσματικότητας κατά τη διαχείριση ασθενών με καρκίνο του πνεύμονα στην Ελλάδα: ένα νέο θεωρητικό υπόδειγμα …

Β Φραγκουλάκης - 2012 - didaktorika.gr
Εισαγωγή: Η οικονομική αξιολόγηση συγκρίνει το κόστος και το όφελος που προκύπτει από
μια νέα θεραπευτική παρέμβαση, προκειμένου να μεγιστοποιήσει την υγεία του πληθυσμού …

Regression analysis of indicating multiple incremental cost-effectiveness ratios for non-small cell lung cancer treatment

N Nakahara, I Kamae - Journal of Medical Economics, 2014 - Taylor & Francis
Objectives: The value of a health technology can be measured in terms of cost and benefit
on two-dimensional co-ordinates. This study is to quantitatively analyze the correlation and …

Assessing the cost-effectiveness of therapies in the third quadrant on the cost-effectiveness plane

B Nemeth, B Eder - Value in Health, 2015 - valueinhealthjournal.com
Objectives Cost-effectiveness of health technologies is shown by their location relative to
their comparators on the cost-effectiveness plane. The plain is divided into four quadrants by …

The analysis of costs and reimbursements for lung cancer treatment in the Czech Republic

V Rogalewicz, J Simrova, R Vojtisek… - Value in …, 2013 - valueinhealthjournal.com
Objectives Lung cancer is the most frequently diagnosed oncologic disease worldwide,
annually diagnosed in nearly 1.4 million patients. In 2010, the incidence in men was 89.7 …

A trial-based EuroQol EQ-5D health utility analysis in patients with previously treated advanced NSCLC

M Huang, J Pellissier, J Liao - Value in Health, 2016 - valueinhealthjournal.com
Objectives This study evaluated health-related quality of life utility in advanced NSCLC
patients who have experienced disease progression after platinum-containing …

Quantitative cost‑effectiveness index of cancer treatments

Z Wu, Y Yang, D Chen - Medicine International, 2023 - spandidos-publications.com
In spite of advancements being made in technology and treatment strategies, which have
markedly improved the survival rate of patients, the cost of cancer care worldwide has …

Estimated direct costs of non-small-cell lung cancer by stage and care phase: a whole disease model

G De Luca, A Buja, M Rivera, A De Polo… - European Journal of …, 2020 - academic.oup.com
Background Non-small-cell lung cancer (NSCLC) is the first cause of cancer-related death
among men and the second among women worldwide. It also poses an economic threat to …

Efektywność kosztowa leczenia nowotworu krtani

M Ściesińska, A Sinkiewicz, MA Kowalkowska… - Farmacja …, 2022 - omega.umk.pl
Obtaining progress in medicine is a costly thing, especially In oncology where it seems to be
the most expensive. Laryngeal cancer is the second most common cancer of the respiratory …

Direct Costs and Healthcare Resource Use Associated with Advanced Non-Small Cell Lung Cancer Management in Previously Treated Patients in Portugal

FV Lopes, F Barata, E Teixeira… - Value in …, 2016 - valueinhealthjournal.com
Objectives To estimate the healthcare resource use (HCRU) and resulting costs associated
with the management of advanced non-small cell lung cancer (NSCLC) in previously treated …

Η οργανωτική προσέγγιση στην αξιολόγηση της ποιότητας χειρουργικής φροντίδας ασθενών με καρκίνο του πνεύμονος

Χ Οικονομοπούλου - 1998 - didaktorika.gr
ΣΚΟΠΟΣ ΤΗΣ ΜΕΛΕΤΗΣ ΗΤΑΝ Η ΑΞΙΟΛΟΓΗΣΗ ΤΗΣ ΠΟΙΟΤΗΤΑΣ ΧΕΙΡΟΥΡΓΙΚΗΣ
ΦΡΟΝΤΙΔΑΣ ΑΣΘΕΝΩΝ, ΠΟΥ ΥΠΟΒΛΗΘΗΚΑΝ ΣΕ ΧΕΙΡΟΥΡΓΙΚΗ ΕΠΕΜΒΑΣΗ …